Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants (C-015-404)

This study is enrolling participants by invitation only.
Sponsor:
Collaborators:
Statens Serum Institut
Sanofi Pasteur, a Sanofi Company
National Institute of Allergy and Infectious Diseases (NIAID)
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Information provided by (Responsible Party):
Aeras
ClinicalTrials.gov Identifier:
NCT01861730
First received: May 21, 2013
Last updated: October 7, 2015
Last verified: October 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is enrolling participants by invitation only.
  Estimated Study Completion Date: June 2017
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)